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The advent of the 5HT3 receptor antagonists (5HT3 antagonists) in the 1990s and the combination with dexamethasone has
resulted in acute emesis protection in 70% of patients receiving highly emetogenic chemotherapy. Despite complete protection in the
acute phase, however, 40% of patients as yet have symptoms in the delayed phase. 5HT3 antagonists and dexamethasone are only
modestly effective in this delayed phase. Moreover, the antiemetic protection over repeated cycles is not sustained. Neurokinine 1
receptor antagonists (NK1 antagonists) belong to a new class of antiemetic agents that specifically target the NK1 receptor, which is
involved in both the acute and, particularly, the delayed phase of emesis. Clinical studies have demonstrated that the addition of NK1
antagonists to dual therapy with a 5HT3 antagonist plus dexamethasone improves the acute emesis protection by a further 10–15%.
In the delayed phase, the proportion of patients remaining free of emesis increases by even 20–30%. Since the effectiveness of this
triplet combination was found to be sustained over six cycles of chemotherapy, the chance for an individual patient to remain
completely protected during both the acute and the delayed phase over six chemotherapy cycles is nearly doubled.
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Nausea and vomiting are considered as two of the most distressing
side effects of anticancer chemotherapy. Chemotherapy-induced
emesis has a serious impact on a patient’s quality of life and the
possibility to complete the planned chemotherapy successfully.
Cisplatin is most commonly associated with profound nausea and
vomiting, which follows a distinct pattern of an acute phase
(0–24h after the start of chemotherapy) and a delayed phase that
is mostly defined as occurring on days 2–5 after the chemother-
apy. Since severe emesis occurs in virtually all patients who receive
a cisplatin dose of X50mgm
 2, cisplatin-induced nausea and
vomiting has served as the model to test anti-emetic agents for
highly emetogenic chemotherapy (Verweij et al, 1996; Gralla et al,
1999).
CURRENT ROLE OF 5HT3 ANTAGONISTS PLUS
DEXAMETHASONE; ACUTE PHASE
Before the advent of the 5HT3 antagonists, nausea and vomiting
were ranked as the two most distressing side effects of systemic
chemotherapy (Coates et al, 1983). The use of 5HT3 antagonists
(ondansetron, granisetron and tropisetron) has provided complete
acute emesis protection in 50-70% of patients receiving a first cycle
of cisplatin-based chemotherapy (Gralla et al, 1999). The addition
of dexamethasone to 5HT3 antagonists has improved the complete
protection rate by a further 10–15%, resulting in a total complete
acute emesis protection in 65–80% of patients (Gralla et al, 1999).
CROSSOVER BETWEEN 5HT3 ANTAGONISTS IN
ACUTE EMESIS FAILURE
In view of the similarity in chemical structure of the available 5HT3
antagonists it has been assumed for many years, while these agents
all act at the same receptor, that failure to one agent would predict
subsequent failure to all 5HT3 antagonists. This was recently
refuted in a randomised double-blind study in 45 patients who had
acute emesis protection failure on ondansetron plus dexametha-
sone following cisplatin- or cyclophosphamide-based chemother-
apy (De Wit et al, 2001). Patients were randomised to receive in the
next cycle either granisetron 3mg plus dexamethasone, or to
continue on ondansetron 8mg plus dexamethasone. A significant
benefit from crossingover to granisetron was found; of 19 eligible
patients who crossed over to granisetron, nine patients obtained as
yet complete protection, whereas this was observed in one of 21
eligible patients who continued on ondansetron, P¼0.005. Several
large, well-designed, randomised studies have demonstrated
equivalent antiemetic efficacy for ondansetron and granisetron
(Ruff et al, 1994; Navari et al, 1995, Stewart et al, 1995; Perez et al,
1998). Since there appears to be no therapeutical difference
between ondansetron doses ranging from 8 to 32mg (Ruff et al,
1994; Italian Group of Antiemetic Research, 1995; Gandara et al,
1998), these results may indicate that there is no complete cross-
resistance between 5HT3 antagonists, and that patients who have
acute emesis protection failure on one 5HT3 antagonist could be
considered to crossover to another 5HT3 antagonist.
Of note, there is one hypothetical alternative explanation for the
observation. Ondansetron is primarily metabolised by cytochrome
450 enzymes, including CYP 2D6, for which genetic polymorph-
isms have been identified (Fischer et al, 1994; Dixon et al, 1995; Received 24 December 2002; accepted 24 April 2003
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appear not to account for granisetron, which is primarily
metabolised by CYP 3 A (Bloomer et al, 1994). Suboptimal levels
of ondansetron due to extensive or ultrarapid CYP 2D6
metabolism in patients may not have a detectable impact in phase
III trials in unselected patients. In the above clinical trial in
patients selected for reasons of protection failure on ondansetron
however, the successful crossover may be related to differences in
5HT3 antagonist metabolism in these patients.
5HT3 ANTAGONISTS PLUS DEXAMETHASONE:
DELAYED PHASE
Despite the efficacy of 5HT3 antagonists in the initial 24h period
after the start of chemotherapy, the therapeutical role in the
delayed phase is rather limited. Studies have shown that 5HT3
antagonists are more active than placebo against delayed nausea
and emesis, but these agents are not more active or inferior to
dexamethasone alone (Jones et al, 1991; Navari et al, 1995). Also,
dual therapy with a 5HT3 antagonist plus dexamethasone did not
improve the results obtained with dexamethasonea a alone (Italian
Group of Antiemetic Research 1995; Goedhals et al, 1998; Latreille
et al, 1998). As a consequence, many investigators consider
dexamethasone a standard therapy in the delayed phase, whereas
others feel that dual therapy with a 5HT3 antagonist for several
days might theoretically provide some additional benefit, and does
little harm.
With the advent of the 5HT3 antagonists, the spectrum of side
effects associated with chemotherapy has changed from profound
emesis in the acute phase to insidious prolonged and often
debilitating symptoms in the delayed phase. Despite complete
protection in the acute phase, 40% of patients suffer from delayed
nausea and vomiting (Morrow et al, 1996). As these symptoms
occur mostly in the outpatient setting, there may be considerable
underestimation of delayed emesis by health care professionals. It
was recently reported that doctors and nurses predicted the
absence of delayed nausea in 76%, and no delayed vomiting in 91%
of outpatients, receiving a first cycle of moderately emetogenic
chemotherapy, while the actual patient diaries revealed that the
absence of delayed symptoms was only 43, and 59%, respectively,
resulting in a 30% difference between perception and reality
(Grunberg et al, 2002).
In 1983, before the introduction of the 5HT3 antagonists, Coates
et al (1983) reported on a survey in Australia that ranked the side
effects perceived by patients who were receiving chemotherapy.
This study identified vomiting and nausea to be the two most
distressing side-effects. In 1995, the study was repeated in the
Netherlands in a total of 197 patients, all of whom had received
5HT3 antagonists, and 75% of whom in addition had received
dexamethasone (de Boer-Dennert et al, 1997). At a mean number
of four chemotherapy cycles at filling out the questionnaire, the
patients still ranked nausea and vomiting to be number one and
three of the most distressing side effects. These studies show that
nausea and vomiting have remained a significant burden to
patients.
5HT3 ANTAGONISTS ANTIEMETIC EFFICACY IS NOT
MAINTAINED OVER REPEATED CYCLES
It is well recognised that the chance to develop nausea and
vomiting increases with each subsequent cycle of chemotherapy.
Part of this can be explained by anticipatory mechanisms. With
each additional cycle, a patient may have a protection failure on
that occasion. A patient who has experienced post-treatment
nausea and emesis more than once or twice is prone to develop
anticipatory symptoms, and will suffer from emesis again in the
next cycles (Morrow et al, 1997).
Several studies have demonstrated that indeed, and despite the
use of 5HT3 antagonist plus dexamethasone, with each subsequent
cycle of chemotherapy, emesis protection decreases (de Wit et al,
1996, 1998). In the largest study in 125 patients receiving six cycles
of cisplatin-based chemotherapy, despite dual therapy with
granisetron and dexamethasone both in the acute and the delayed
period, the initial complete acute emesis protection decreased from
66 to 39%, and for delayed emesis, the initial complete protection
of 52% decreased to 43, or 21% in the sixth cycle, depending on the
type of statistical analysis. In this study, it was also found that
unsuccessful delayed emesis protection adversely influenced acute
emesis protection in subsequent cycles of chemotherapy (de Wit
et al, 1998). If delayed emesis protection is not improved, most
patients will develop emesis, and in due course both in the acute
and in the delayed phase.
NEW DEVELOPMENTS: NK1 ANTAGONISTS
Substance P is an 11-amino-acid neuropeptide of the tachykinin
family of peptides. It is found in the gut and central nervous
system and can produce vomiting when injected into ferrets
(Watson et al, 1995). The biological actions of substance P are
mediated through a specific neuroreceptor, neurokinin 1 (NK1). A
number of nonpeptide compounds that selectively block the NK1
receptor have been identified, and a typical feature of the NK1
antagonists was that these abolished emesis from a wide range of
profound emetic stimuli, including apomorphine, morphine,
nicotine, copper sulphate, ipecacuanha, radiation, cyclophospha-
mide, cisplatin, and motion in the ferret and the dog (Watson et al,
1995). This wide spectrum of antiemetic activity is not shared by
serotonin- and dopamine receptor antagonists, and suggests that
substance P may exert a critical role in the emetic reflex pathway
and presents an appropriate target for therapeutical intervention
(Hesketh et al, 1999). The potential value of the NK1 antagonists in
the treatment of chemotherapy-induced emesis was first recog-
nised in ferret studies, indicating that both acute and delayed
cisplatin-induced emesis were completely abolished (Rudd et al,
1996). Preliminary observations suggested that similar benefits
might be obtained in patients (Kris et al, 1997). A number of
clinical studies have now confirmed the effectiveness of NK1
antagonists both in the acute and, particularly, the delayed phase.
NK1 RECEPTOR ANTAGONISTS:
ACUTE AND DELAYED EMESIS
The effectiveness of the addition of the NK1 antagonist CJ-11,974
to standard therapy with granisetron plus dexamethasone was
investigated in a randomised, placebo-controlled, phase II study in
a total of 61 patients receiving a first cycle of cisplatin-based
chemotherapy (Hesketh et al, 1999). Granisetron and dexametha-
sone were administered once before the cisplatin infusion, neither
drug was continued on subsequent days. CJ-11,974 100mg, or
placebo, was administered orally, before and 12h after cisplatin
and then twice daily on days 2–5. The primary endpoint was the
percentage of patients who developed delayed emesis. In patients
on CJ-11,974, complete control of delayed emesis was obtained in
68 vs 37% in the patients who received placebo. There was also a
numerical advantage for complete control of emesis on day 1 in
favour of the CJ-11,974 containing group, 86 vs 67%, but this
difference did not reach statistical significance with this limited
number of patients.
Simultaneously with this trial report, a randomised phase II
study of the NK1 antagonist L-754,030 (also known as MK-869)
was published (Navari et al, 1999). This trial involved 159 patients.
The standard treatment of granisetron plus dexamethasone in all
patients was identical to that used in the above-mentioned study.
The patients were randomised to receive L-745,030 400mg orally
5HT3 and NK1 antagonists
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cisplatin followed by placebo on days 2–5, or placebo both before
and after cisplatin. In the acute-emesis phase, 93% of the patients
in the L-754,030 groups and 67% of those receiving granisetron
plus dexamethasone plus placebo had no vomiting (Po0.001). In
the delayed-emesis phase, 82% of the patients receiving L-754,030
on all 5 days, 78% of those receiving L-754,030 only on day 1, and
33% of those receiving standard therapy had no vomiting (Po0.01
for the comparison of the active drug groups vs placebo). The
median nausea score in the delayed-emesis phase was significantly
in favour of the active drug for 5 days group. The numerical 4
percentage points further improvement obtained by continued
dosing of L-754,030 on days 2–5 as compared to L-754,030 only on
day 1 did not reach statistical significance, which may have been
attributed by the modest sample size of the study.
More recently, the preceding proof of concept studies conducted
with L-745,030, and its water-soluble intravenous prodrug L-
758,298, were published (Cocquyt et al, 2001; Van Belle et al, 2002).
The rationale for combining NK1 antagonists with 5HT3 antago-
nists is based upon the results of these phase II studies. In the first
study, L-758,298 was directly compared with ondansetron in a
randomised double-blind study in 53 patients receiving a first
cycle of cisplatin (Cocquyt et al, 2001). The study evaluated the
prevention of both acute and delayed emesis. In the acute period,
the proportion of patients without emesis in the L-752,298 and
ondansetron groups was 37 and 52%, respectively. In the delayed
period, the proportion of patients without emesis in the L-758,298
and ondansetron treatment groups was 72 and 30%, respectively
(P¼0.005). Hence, the single dose of L-758,298 substantially
suppressed delayed emesis. Although L-758,298 also appeared to
reduce acute emesis post-cisplatin, there was a numerical
advantage in acute protection for ondansetron. The study also
provided solid data to support the hypothesis that the transition
from the acute emesis phase to the delayed phase starts
considerably earlier than 24h after cisplatin administration
(Horgan et al, 2001). It was found that the time course of acute
vomiting following L-758,298 and ondansetron was quite distinct.
The median time to first vomiting was 4.46 and 12.25h in the
L-758,298 and ondansetron groups, respectively. All acute failures
in the L-758,298 group occurred in the first 8h. These results
indicate that later, but not ‘early’ acute vomiting is primarily
substance P mediated and that, conversely, serotonin-mediated
mechanisms may play a more important role during the ‘‘early’’
acute period. This finding provides a strong rationale to combine
5HT3 antagonists and NK1 antagonists to optimise acute emesis
control.
Further data to support triple therapy with a 5HT3 antagonist,
dexamethasone plus an NK1 antagonist were obtained in a
randomised study involving 177 cisplatin-naive patients (Van
Belle et al, 2002). Patients were randomized to one of three groups
as follows: group I received L-758,298 intravenously plus
dexamethasone before cisplatin on day 1, followed by L-745,030
orally on days 2–5; group II received L-758,298 plus dexametha-
sone on day 1, followed by placebo on days 2–5; and group III
received ondansetron i.v. plus dexamethasone on day 1, followed
by placebo on days 2–5. Additional (rescue) medication was
available for emesis or nausea at any time. The primary efficacy
parameters were the proportions of patients with no emesis and
the proportion of patients without emesis or rescue therapy on day
1, and on days 2-5. Since use of rescue therapy is a clear measure of
existing nausea that interferes with daily life, this composite end
point of complete response appropriately evaluates both vomiting
and nausea parameters. Dual therapy with ondansetron and
dexamethasone (group III) was superior in controlling acute
emesis (83% no emesis and no rescue vs 40% in groups I and II
combined, Po 0.001), whereas the proportions of patients with no
emesis and no use of rescue medication in the delayed phase were
significantly better in the L-758,298 plus continued dosing (59%)
and L-758,298 single dose (46%) groups as compared with the
ondansetron plus dexamethasone group (38%), Po0.05 for group
I vs group III. The numerical advantage for continued dosing with
L-745,030 did not reach statistical significance with this limited
sample size.
In conclusion, both studies lend support to the proposition that
the underlying mechanisms of acute and delayed emesis are
different, that 5HT3 antagonists are active in the acute phase, that
NK1 antagonists are active in both the acute and, particularly, the
delayed phase, and that the results warrant to test the potential of
the combined use of a 5HT3 antagonist plus an NK1 antagonist.
The numerical advantages reported by Navari and by Van Belle,
which were both in favour of continued dosing with L-745,030,
suggest that continued dosing may further enhance control of
delayed emesis.
The first of the subsequent phase II b studies, which has been
published as a full paper, investigated the triple regimen of
granisetron, L-745,030 and dexamethasone vs granisetron and
dexamethasone alone (Campos et al, 2001). In this trial, a total of
351 patients were randomised to four groups: group I received
granisetron plus dexamethasone pre-cisplatin followed by placebo
on days 2–5; group II received granisetron/dexamethasone plus L-
745,030 orally pre-cisplatin, followed by L-745,030 orally on days 2
to 5; group III received dexamethasone pre-cisplatin and L-745,030
the evening before and pre-cisplatin, plus continued dosing with L-
745,030; group IV received dexamethasone plus L-745,030 pre-
cisplatin, plus continued dosing with L-745,030. Triple therapy
with L-745,030 provided 23% additional complete emesis protec-
tion as compared with dual therapy with granisetron plus
dexamethasone alone, 80 vs 57%, respectively, Po0.05. The
importance for keeping the 5HT3 antagonist in the regimen to be
used in the acute phase was again shown by the inferior results in
the acute phase in groups III and IV (43 and 46%, respectively,
Po0.05 as compared with group II). In the delayed phase, all three
groups receiving L-745,030 had superior protection as compared
with group I; the proportion of patients without emesis in groups I,
II, III and IV was 29, 63, 51 and 57%, respectively, Po0.01 for
groups II, III and IV vs group I.
The study demonstrated with sufficient statistical power that the
triple combination of a 5HT3 antagonist and dexamethasone, plus
an NK1 antagonist provided the best protection against acute
emesis, and also confirmed and extended the previous findings
that with the use of an NK1 antagonist, the control of delayed
emesis is substantially enhanced.
NK1 receptor antagonist efficacy over repeated cycles
In a similar phase II b study design, comparing triple therapy with
dual therapy, the sustainment of antiemetic efficacy was investi-
gated during six cycles of cisplatin-based chemotherapy (de Wit
et al, 2002). All 202 patients received intravenous ondansetron and
oral dexamethasone pre-cisplatin, and oral dexamethasone on
days 2–5 of each cycle. The L-745,030 used in this study was the
definitive formulation, which has obtained the generic name
aprepitant (Merck Inc., West Point PA, USA). Patients were
assigned in a blinded fashion to receive one of the following three
regimens; group I, aprepitant 375mg before cisplatin on day 1 and
aprepitant 250mg on days 2–5 (N¼35); group II, aprepitant
125mg before cisplatin on day 1 and aprepitant 80mg on days 2-5
(N¼81); group III placebo before cisplatin on days 2–5 (N¼86).
During the study, new pharmacokinetic data with the final
formulation in healthy subjects became available that showed that
the plasma levels of aprepitant attained with the 375mg regimen
were higher than expected, and a pharmacokinetic interaction was
found to exist between the 375mg regimen and dexamethasone.
The 375/250mg dose regimen (group I) was therefore discon-
tinued. The primary end point was complete response (no emesis
and no rescue therapy) during the overall period, defined as
5HT3 and NK1 antagonists
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discontinuation of group I, the efficacy evaluations focused on the
aprepitant 125/80mg dose (group II) compared with standard
therapy (group III). A cumulative probability analysis using the
model for transitional probabilities was used to analyse the data, as
was also applied in the previous multiple cycle studies with 5HT3
antagonists (de Wit et al, 1996, 1998). In the first cycle, the
percentages of patients with complete response (0–120h) were
64% in the aprepitant 125/80mg (plus standard therapy) group
and 49% in the standard therapy alone group, Po0.05. Thereafter,
the percentages for aprepitant 125/80mg ranged from 64% in cycle
2 to 59% by cycle 6, and those for standard therapy further
declined to 34% by cycle 6. Statistical significance was achieved for
between-treatment differences for cycles 5 and 6. Results for
aprepitant 375/250mg were similar to those obtained for
aprepitant 125/80mg. The reasons for discontinuation and the
drop-out rates were comparable across the treatment groups.
Hence, the efficacy of the triple therapy was sustained through
all six cycles, unlike that of the 5HT3 antagonist plus dexametha-
sone standard therapy, which further decreased. The benefit of
triple therapy over standard therapy was clinically apparent as an
almost two-fold increase (from 34 to 59%) in a patient’s chance of
remaining free of emesis and of the need for rescue medication
during all of 5 days post-treatment and through six cycles of
cisplatin-based chemotherapy.
CONCLUSIONS
With the introduction of the 5HT3 antagonists in the 1990s and the
combination with dexamethasone, complete acute emesis protec-
tion became possible in 70% of patients receiving a first cycle of
highly emetogenic chemotherapy. 5HT3 antagonists and dexa-
methasone, however, are not very effective in the delayed phase.
Even following complete protection in the acute phase, 40% of
patients as yet have delayed symptoms, which interfere with daily
life. As these symptoms typically occur in the outpatient setting,
the impact is underestimated by health care professionals.
Moreover, the incidence of both acute and delayed emesis
increases with each cycle of chemotherapy, and after six cycles
of emetogenic chemotherapy, the greater majority of patients
suffer from delayed emesis and more than half of the patients have
acute emesis as well, despite the use of dual therapy with a 5HT3
antagonist plus dexamethasone.
Recent data have shown that besides serotonin-mediated
mechanisms in acute emesis (where 5HT3 antagonists fulfil their
efficacy), substance P is another neuropeptide with a major role in
the acute as well as, particularly, the delayed phase of emesis.
Substance P exerts its effects by binding to a specific neuror-
eceptor, NK1. A number of nonpeptide compounds that selectively
block the NK1 receptor have now been identified. Most of the data
have been obtained with L-745,030, also known as MK-869, and the
current generic name aprepitant. Studies in highly emetogenic
chemotherapy have shown that the addition of aprepitant to dual
therapy with a 5HT3 antagonist plus dexamethasone increases the
acute emesis protection by a further 10–15%. The proportion of
patients remaining free of emesis during the delayed emesis
period, or when measured during all of 5 days following
chemotherapy, increases by 20–30%. Moreover, the study results
have shown that the protection against chemotherapy-induced
nausea and vomiting is sustained over repeated cycles in patients
receiving triple therapy including aprepitant. The confirmatory
phase III trials have recently been completed and the data have
been submitted for regulatory review, both in the US and in
Europe.
The addition of these new NK1 antagonists to the existing 5HT3
plus dexamethasone combination appears to be another major leap
forward in the successful protection against chemotherapy-
induced emesis, which will become available in clinical practice
soon.
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